Study periods | Assessment 1 (Baseline) | Assessment 2 | Assessments 3, 4 and 5 |
---|---|---|---|
Time (weeks) | 0 | 4 | 52, 104, 156 |
Inclusion/Exclusion Criteria | X | Â | Â |
Written Informed Consent | X | Â | Â |
Patient characteristics | X | Â | Â |
Medical History | X | Â | Â |
Retentiona | X | X | X |
Opioid agonist prescriptiona | X | X | X |
Treatment adherencea | X | X | X |
Frequency of visitsa | X | X | X |
Treatment Outcomes Profile (TOP)b | X | X | X |
Health section of Opiate Treatment Index (OTI)b, including nose-related problems | X | X | X |
Symptom-Checklist 27 (SCL-27)b | X | X | X |
Adverse Eventsb | X | X | X |
Opioid Agonist Scale1,c | X | X | Â |
VAS Subjective effects2,c | X | X | Â |
VAS Cravingc | X | X | X |
VAS Satisfactionc | X | X | X |